Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company Drug

GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk

Fineline Cube May 19, 2026
Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Company Deals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Fineline Cube Jul 31, 2025

China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...

Company Deals

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal

Fineline Cube Jul 31, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...

Company Deals

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China

Fineline Cube Jul 31, 2025

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...

Company Drug

Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 31, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...

Company Deals

Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion

Fineline Cube Jul 31, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...

Company Drug

Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622), a leader in ophthalmic solutions, today announced that its...

Company Deals

Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with...

Company Deals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Fineline Cube Jul 31, 2025

China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...

Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

Fineline Cube Jul 31, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...

Company Deals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

Fineline Cube Jul 31, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...

Company Drug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL

Fineline Cube Jul 31, 2025

The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...

Company Drug

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial

Fineline Cube Jul 30, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...

Company Drug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Fineline Cube Jul 30, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...

Company Drug

Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment

Fineline Cube Jul 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...

Company Deals

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics

Fineline Cube Jul 30, 2025

LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

Fineline Cube Jul 30, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Others

China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Jul 30, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...

Company

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows

Fineline Cube Jul 30, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...

Company

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered

Fineline Cube Jul 30, 2025

Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...

Posts pagination

1 … 122 123 124 … 667

Recent updates

  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
  • Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator
  • GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk
  • Taiji Industry Secures NMPA Clinical Trial Approval for DSC158A, Next-Generation Influenza RNA Polymerase Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Company Drug

GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.